Legislative News, Studies and Analysis - GENERIC …...cancer ($11.6 billion), anti-bacterials...

S E V E N T H A N N U A L E D I T I O N : 2 0 1 5

GENERIC DRUGSAVINGS IN THE U.S.

GENERIC DRUG SAVINGS IN THE U.S. REPORT 2015 PAGE 1

Rising health care costs continue to be a major concern for everyone from patients to policymakers. But there is some good news. Savings from generic drugs reached an all-time high in 2014, according to the seventh annual Generic Drug Savings in the United States report, compiled on behalf of the Generic Pharmaceutical Association (GPhA) by the IMS Institute for Healthcare Informatics.

The 2015 report shows that generic drugs are an essential part of any solution to sustaining our health system and are central to efforts that increase patient access and generate savings for patients, taxpayers, employers, payers, providers and others.

Nearly 3.8 billion of the total 4.3 billion prescriptions dispensed in the U.S. in 2014 were filled using generic drugs. This means that generic drugs now account for nearly nine out of every 10 (88%) prescriptions dispensed in the United States. Yet generic prescriptions account for only 28% of total drug spending.

Generic drugs were responsible for $254 billion in health system savings in 2014, bringing the total savings over the last 10 years to $1.68 trillion. Generic drug manufacturers can proudly point to a legacy of savings and access that brings expensive treatments within reach for millions of people. It is important to note that savings are growing and are expected to continue to grow.

ANNUAL GENERIC DRUG SAVINGS IN THE UNITED STATES

254 BILLION SAVINGS

GENERIC DRUGS IN THE UNITED STATES

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

$50 Billion

$100 Billion

$150 Billion

$200 Billion

$250 Billion

$300 Billion

0

87 98

116

135161

177197

213

246 254

Historic savings have been revised to include standard data restatements.

1.68 TRILLION 10-YEAR SAVINGS (2005 - 2014)

88% OF PRESCRIPTIONSbut only 28% of drug costs3.8 BILLION PRESCRIPTIONS

ONLY

28%DRUG COST


EXPERTS AGREE: GENERIC DRUG SAVINGS ARE WIDELY RECOGNIZED AS A LONG-TERM SOLUTION TO RISING HEALTH COSTS

• The 2014 Express Scripts Drug Trend Report shows that SINCE 2008, THE PRICE OF BRAND DRUGS HAS ALMOST DOUBLED but the PRICE OF GENERIC DRUGS HAS BEEN CUT ROUGHLY IN HALF.

• A May 2015 report from AARP notes that RETAIL PRICES FOR GENERIC DRUGS FELL AN AVERAGE OF 4% IN 2013, marking nearly a decade of consecutive years of decreasing generic drug costs. That report also notes that 73% OF GENERIC DRUGS in the study EXPERIENCED PRICE DECREASES.

• An August 2015 Drug Channels blog noted that in the SECOND QUARTER OF 2015 ALMOST HALF (44%) OF GENERIC DRUGS EXPERIENCED A DECLINE IN COST.

Newer generic drugs (introduced within the last 10 years) are making significant impacts on patient and health system savings. Newer generics make up more than half (57%) or $145 billion of the $254 billion saved in 2014. These newer generic drugs also saved the health system $638 billion of the most recent decade’s $1.68 trillion. Older generics generated upwards of $100 billion in health system savings in 2014 and $1.05 trillion in savings in the last ten years.

The most effective way to keep costs low is to increase competition. GPhA believes that there are several ways policymakers can help increase generic competition.

First, in partnership with the industry, Congress should encourage timely FDA review of the more than 3,800 generic drug applications that have been filed with the Agency and await regulatory action. Once those products are approved and enter the market, consumers will have more options and that helps prices drop.

“Patients, taxpayers and others will find no better partner than the generic industry in efforts to reduce health expenses and promote savings and access. The best way to accomplish this is to increase competition from generic drugs.“

- Chip Davis, President and CEO, Generic Pharmaceutical Association

Second, Congress should review the abuse by some brand drug companies of FDA programs designed to protect patient safety. Misuse of these programs, such as Risk Evaluation and Mitigation Strategies (REMS), prevents generic drugs from entering the market and reaching patients, which dampens competition and can keep drug prices high. This misuse comes at a cost of $5.4 billion annually to our health system, according to a separate analysis conducted in 2014 by Matrix Global Advisors.

Congress can also encourage the FDA to increase competition for biologics by implementing regulations and policies for approving biosimilar products. This includes supporting a biosimilar naming system and interchangeability policy that encourages competition from safe, more affordable biosimilar medicines. These policies would provide American consumers with more choices, greater access to medicines, and billions of dollars in increased savings.

GENERIC DRUG SAVINGS IN THE U.S. REPORT 2015

$2B $4B $6B $8B $10B $12B $14B $16B $18B $20B $22B $24B $26B $28B $30B $32B $34B $36B $38B

PAGE 3

GENERIC DRUG SAVINGS BY THERAPY (2014)

Generic drug manufacturers continue to invest in innovation. America’s generic drug industry is constantly introducing new generic therapies and finding faster, smarter, safer ways to manufacture medicines that translate into savings and access for millions of people.

In 2014, the majority of generic drug savings are accrued in therapy areas that address mental health conditions ($38.0 billion), treat hypertension ($27.9 billion), or help manage or lower cholesterol levels ($26.8 billion). Rounding out the top 10, therapy area savings are accrued in pain medicines ($22.8 billion), anti-ulcerants ($19.2 billion), nervous system disorders ($15.6 billion), anti-nauseants for cancer ($11.6 billion), anti-bacterials ($11.3 billion), other central nervous system disorders ($9.4 billion), and attention deficit hyperactivity therapies ($8.2 billion).

With respect to oncology treatments, the National Cancer Institute reports that breast cancer affects nearly 3 million people annually, making it the second most common cancer. Generic drugs for breast cancer and other cancers saved $4.1 billion in 2014. Prostate cancer is second only to skin cancer as the most common cancer in men. Savings from prostate cancer generic drugs totaled $765 million in 2014. Savings from generics used to treat depression, a disease that affects 19 million Americans, totaled $23.3 billion in 2014. About one in 26 Americans will develop a seizure disorder such as epilepsy. Generic anti-seizure drugs saved the health system $13.8 billion in 2014.

GENERIC DRUG SAVINGS BY THERAPY AREA

MENTAL HEALTH

HYPERTENSION

CHOLESTEROL

PAIN

ANTI-ULCERANT

NERVOUS SYSTEM DISORDERS

CANCER ANTI-NAUSEANTS

ANTIBACTERIALS

OTHER CNS

ADHD

ANTICOAGULANTS

ONCOLOGY

DIABETES

DERMATOLOGICS

RESPIRATORY

BPH

ANTI-ALZHEIMERS

OSTEOPOROSIS

OTHER

$38.0 BILLION

$27.9 BILLION

$26.8 BILLION

$22.8 BILLION

$19.2 BILLION

$15.6 BILLION

$11.6 BILLION

$11.3 BILLION

$9.4 BILLION

$8.2 BILLION

$7.6 BILLION

$7.5 BILLION

$6.8 BILLION

$6.0 BILLION

$4.8 BILLION

$3.9 BILLION

$2.1 BILLION

$1.8 BILLION

$22.4 BILLION

GENERIC DRUG SAVINGS IN THE U.S. REPORT 2015 PAGE4

It is evident that annual spending on many medication classes would soar in the absence of generic competition. This underscores the need to sustain the generic drug industry and actively pursue policies that support or grow, rather than undermine, patient and health system savings from generic drugs.

The need for prescription medicines typically increases with age and the savings made possible by generic drug use among older adults and seniors is critical to sustaining affordable health care. More than one-third (36%) of the total savings in 2014, or $92 billion, came from generic drugs used by seniors age 65 and up. The healthcare system saved $111 billion because of generic use by older adults.

Nearly 20 percent of the $254 billion in total savings in 2014 stemmed from the use of generic drugs by children and young adults. Generic drug use by children and teens generated $16 billion (6%) in savings while young adults (age 20-39) generated an additional $34 billion (13%) of the total savings.

SAVINGS FROM GENERIC DRUGS FOR SENIORS AND PUBLIC PROGRAMS

ANNUAL THERAPY AREA SPENDING SOARS WITHOUT GENERICS

HYPERTENSION CHOLESTEROL* ANTIDEPRESSANTS ANTI-ULCERANTS ANTI-PSYCHOTICS** EPILEPSY ONCOLOGY ANTI-COAGULANTS RESPIRATORY DIABETES ANTI-BACTERIAL ALZHEIMER’S

$2 Billion

$4 Billion

$6 Billion

$8 Billion

$10 Billion

$12 Billion

0

$14 Billion

$16 Billion

$18 Billion

$20 Billion

$22 Billion

$24 Billion

$26 Billion

$28 Billion

$30 Billion

$32 Billion

$34 Billion

$36 Billion$27.9 B

$26.8 B$23.2 B

$19.2 B

$14.8 B$13.8 B

$7.6 B $4.8 B$6.8 B

$5.4 B

$2.1 B

Savings

2014 Estimated Additional Spending inAbsence of Generic Competition

2014

2014 Actual Spending

$7.5B


GENERIC SAVINGS BY PAYOR

Seniors (65+):

$92 BILLIONIN SAVINGS

Older Adults (40-64):


Young Adults (20-39):


Children (0-19):


GENERIC SAVINGS BY PATIENT AGE

While the majority of savings are attributed to the commercially insured, the federal government is the single largest purchaser of generic drugs in the United States, primarily through Medicaid and Medicare. According to the Centers for Medicare and Medicaid Services (CMS), there are 72 million Medicaid beneficiaries and another 54 million enrolled in Medicare.

Spending on medicines in each of these programs would nearly double without the availability of generic drugs. In Medicare, for instance, spending for medicines would have reached approximately $160 billion without the $76.1 billion in savings achieved by using generics in 2014. Nationally, Medicare enrollee savings per capita was $1,923 last year.

In the Medicaid program, estimated spending reached $26.1 billion in 2014, with savings from generics totaling $33.5 billion. Without generic savings, the Medicaid drug tab would have reached nearly $60 billion. That translates to Medicaid savings of $479 per enrollee attributed to generic drugs. These savings are essential for the vital government programs that protect our lower-income and older citizens.

CASH (non-enrolled): $15.8 billion

COMMERCIALLY INSURED (includes exchanges): $128 billion

MEDICAID: $33.5 billion; $479 per enrolleeMEDICARE: $76.1 billion; $1,923 per enr ollee6%

13%

51%30%


State savings, particularly for public programs, continue to help taxpayers and strained program budgets. Medicaid is operated differently across states and it is important to note that this report is not ranking or evaluating the merits of any particular state programs in this analysis. Evaluation or comparison beyond the savings data highlighted here requires a separate and more thorough analysis that accounts for variables such as generic efficiency, distribution method, population and other demographic factors.

Savings from the use of generics by Medicare, Medicaid, the commercially insured, and non-insured patients resulted in an average of $5 billion per state. The highest per capita Medicaid savings were accrued by Kentucky, West Virginia, Maine, Rhode Island and Massachusetts.

New York saved $3.9 billion, California saved $2.9 billion and Texas, a state with 4.7 million Medicaid enrollees, saved $1.7 billion. For detailed state-by-state findings, please see the report appendix.

There has never been a more important time to sustain and grow savings from generic drugs. GPhA and its member companies look forward to working with Congress, the FDA and stakeholders from all corners of the supply chain to ensure that measures that encourage pharmaceutical competition and expand access without compromising patient safety are given thoughtful consideration.

GPhA and its membership are committed to delivering savings and enhancing access to affordable medicines for all Americans. The generic drug industry’s 30-year track record of savings is unequalled in healthcare. Still, the potential for growth and expansion is great. Increasing health savings and expanding access to medicine will continue to be a priority for this industry and all who strive to promote the sustainability of our nation’s health care system.

MEDICAID AND MEDICARE SAVINGS PER ENROLLEE

MEDICARESAVINGS

$76.1BILLION $1,923

Per Average Enrollee

MEDICAIDSAVINGS

$33.5BILLION $479

Per Average Enrollee


APPENDIX

I. GENERIC SAVINGS: STATE-BY-STATE ($)

MEDICAID MEDICARE CASH COMMERCIAL TOTALALABAMA 444,851,779 1,802,393,720 387,795,708 2,771,621,529 5,406,662,736

ALASKA 39,678,170 54,903,180 25,689,539 195,233,167 315,504,056

ARIZONA 651,848,266 1,277,759,282 280,085,049 2,282,206,206 4,491,898,803

ARKANSAS 356,121,682 1,028,723,148 270,810,691 1,582,775,188 3,238,430,709

CALIFORNIA 2,896,471,432 6,964,739,108 1,302,777,776 10,332,598,166 21,496,586,482

COLORADO 399,054,698 698,640,258 220,741,342 1,623,080,190 2,941,516,488

CONNECTICUT 487,198,605 814,457,553 142,188,288 1,497,180,219 2,941,024,665

DELAWARE 155,910,372 186,896,196 35,827,082 337,820,890 716,454,540

DISTRICT OF COLUMBIA 161,539,568 161,716,513 32,105,892 394,496,255 749,858,228

FLORIDA 1,684,543,656 5,404,597,240 1,122,243,980 6,835,958,584 15,047,343,460

GEORGIA 931,489,983 2,458,908,926 723,672,992 4,244,424,056 8,358,495,957

HAWAII 137,797,928 255,346,611 48,718,237 382,103,556 823,966,332

IDAHO 127,702,619 304,849,301 94,462,313 574,293,261 1,101,307,494

ILLINOIS 1,285,130,830 2,720,922,627 640,058,619 5,125,514,696 9,771,626,772

INDIANA 605,553,217 1,645,604,054 382,449,067 2,963,300,806 5,596,907,144

IOWA 358,377,591 907,585,619 162,079,085 1,430,541,569 2,858,583,864

KANSAS 230,436,775 719,773,896 230,547,468 1,474,954,932 2,655,713,071

KENTUCKY 1,098,648,233 1,634,353,302 341,225,103 2,246,046,266 5,320,272,904

LOUISIANA 556,884,346 1,501,092,152 385,962,582 2,602,068,503 5,046,007,583

MAINE 228,201,849 305,872,924 38,236,119 571,010,047 1,143,320,939

MARYLAND 778,326,627 921,962,289 237,944,247 2,338,411,956 4,276,645,119

MASSACHUSETTS 1,116,765,783 1,669,762,815 195,928,917 3,088,530,695 6,070,988,210

MICHIGAN 1,140,867,964 2,581,234,679 598,371,985 4,300,916,599 8,621,391,227

MINNESOTA 473,365,226 1,163,989,095 236,510,463 1,992,074,023 3,865,938,807

MISSISSIPPI 241,175,220 1,119,694,512 308,418,363 1,541,800,025 3,211,088,120

MISSOURI 579,786,676 1,668,473,366 378,498,506 2,798,437,872 5,425,196,420

MONTANA 67,756,531 193,748,347 64,434,941 355,851,516 681,791,335

NEBRASKA 159,389,664 540,019,433 122,841,651 923,415,374 1,745,666,122

NEVADA 262,779,539 501,906,214 119,046,929 1,001,786,421 1,885,519,103

NEW HAMPSHIRE 68,343,246 261,388,896 44,738,213 587,495,486 961,965,841

NEW JERSEY 887,990,448 1,843,530,433 320,150,714 3,224,123,408 6,275,795,003

NEW MEXICO 147,374,037 361,065,998 100,158,340 740,058,272 1,348,656,647

NEW YORK 3,916,879,368 6,512,990,393 702,219,894 8,867,475,384 19,999,565,039

NORTH CAROLINA 921,047,904 2,780,321,465 574,871,170 4,402,999,023 8,679,239,562

NORTH DAKOTA 55,923,995 195,739,194 57,489,065 344,152,806 653,305,060

OHIO 1,723,663,137 3,075,465,603 606,676,053 5,217,740,415 10,623,545,208

OKLAHOMA 372,437,674 862,722,757 262,164,002 1,740,192,443 3,237,516,876

OREGON 417,931,739 802,402,711 146,378,892 1,314,892,129 2,681,605,471

PENNSYLVANIA 1,641,835,713 3,803,198,250 478,488,768 6,053,663,255 11,977,185,986

RHODE ISLAND 192,058,518 383,580,682 32,673,629 584,286,498 1,192,599,327

SOUTH CAROLINA 407,836,736 1,399,159,991 292,421,289 2,232,625,274 4,332,043,290

SOUTH DAKOTA 56,861,026 210,260,694 55,436,578 344,308,340 666,866,638


MEDICAID MEDICARE CASH COMMERCIAL TOTALTENNESSEE 754,657,833 2,357,962,208 489,837,541 3,513,613,089 7,116,070,671

TEXAS 1,692,398,872 4,922,319,889 1,410,237,858 9,950,792,330 17,975,748,949

UTAH 138,199,190 392,810,316 201,257,810 1,285,690,748 2,017,958,064

VERMONT 89,998,513 131,927,191 11,724,094 209,543,405 443,193,203

VIRGINIA 414,657,032 1,581,925,297 339,366,733 3,901,376,278 6,237,325,340

WASHINGTON 692,416,756 1,038,784,866 253,278,727 2,411,355,581 4,395,835,930

WEST VIRGINIA 524,707,512 738,949,139 96,946,022 1,031,041,848 2,391,644,521

WISCONSIN 680,614,308 1,167,781,230 232,726,109 2,293,231,553 4,374,353,200

WYOMING 30,971,617 84,671,899 27,693,272 204,946,028 348,282,816

TOTAL 33,486,460,003 76,118,885,462 15,866,607,707 128,264,056,160 253,736,009,332

II. METHODOLOGY

The IMS Institute for Healthcare Informatics provides key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. It is a research-driven entity with a worldwide reach that collaborates with external healthcare experts from across academia and the public and private sectors to objectively apply IMS Health’s proprietary global information and analytical assets. More information about the IMS Institute can be found at http://www.theimsinstitute.org.

The seventh edition of the generic drug savings report was created using ten years of sales and volume data from the IMS MIDAS database. An examination of all brand and generic medicines sold in the United States between 2004 and 2014 resulted in the identification of 235 molecules that became available as generics between 2005 and 2014 and 441 molecules that were available as generics prior to 2005.

The value of generics currently on the market was estimated using the pre-expiry invoice prices of the brands they replaced. The current dataset includes pre-expiry brand prices for the 235 newly generic molecules. Pre-expiry brand prices for the 441 older generics were pulled forward from previous editions of the study. The value of each generic molecule was determined by multiplying its pre-expiry brand price by the generic volume sold in each of the last ten years. This value represents what would have been spent on brand name medicines in the absence of generic competition.

The savings attributed to each of the 622 generic molecules was determined by subtracting historic generic spending from the estimated brand spending in the absence of generic competition.

State level generic savings was estimated by apportioning total savings for each molecule by each state’s share of the national retail prescription volume. This method embeds two simplifying assumptions; first, that prices are uniform across the country, and second, that retail prescription activity mirrors prescription activity in other channels, notably mail order.

Savings by pay type was estimated using the share of each molecule dispensed via retail pharmacies to patients paying with cash and those covered by Medicare, Medicaid, and commercial insurance. After calculating savings at the molecule, state, and payer level, results were summed to the state-payer level. This method does not analyze the cost to the patient who may have a co-pay or discount card; rather it divides generic savings equally amongst patients based on prescription use, regardless of insurance plan.


NOTES & LIMITATIONS

This analysis was refreshed with annual sales and volume data for all medicines sold in the United States between 2004 and 2014. Savings from newer generics launched in the 2005 to 2014 study period is based on the most current knowledge of their pre-expiry prices. Savings from generics launched prior to 2005 were calculated using prices calculated in previous editions of the study.

Generic savings were calculated at the molecule-class level using a single average price for each molecule across all formulations (oral solid, liquid, injectable). Molecules that are available in multiple formulations are assumed to have the same pre- and post-expiry utilization patterns.

State level savings were estimated using retail prescription volumes. The state level analysis assumes prescriptions dispensed via mail order pharmacies and institutional settings follow the same patterns as the retail market.

Savings generated by children, young adults, older adults, and seniors were estimated based on national generic prescription trends captured in the IMS National Prescription AuditTM. These figures represent the portion of the national savings, not the personal savings amassed by patients of a certain age.

Patients with Medicaid, Medicare, and commercial insurance pay different prices for their medications based on their insurance benefit design. This analysis did not attempt to estimate savings to individual patients based on their method of payment. Instead, total generic savings for each molecule was divided evenly based on the number of prescriptions filled by patients of each pay type.

www.gphaonline.org


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Alabama $5.4 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).

GPhA welcomes the opportunity to work with policymakers, the FDA and stakeholders from all corners of the supply chain to ensure patient and health system savings. Together, more can be done to encourage pharmaceutical competition and expand access to safe, effective and more affordable generic medicines.


ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION

$1,923Average per Enrollee

Average per Enrollee$479

For more information visit www.gphaonline.org

2014 GENERIC DRUG SAVINGS IN ALABAMA

MEDICAID SAVINGS: $445 Million

MEDICARE SAVINGS: $1.8 Billion

CASH (non-insured) SAVINGS: $388 Million

COMMERCIAL INSURED SAVINGS: $2.8 Billion

TOTAL SAVINGS: $5.4 Billion$5.4 BILLION

GENERIC DRUGS SAVINGS in ALABAMA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Alaska $316 million in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN ALASKA


MEDICARE SAVINGS: $55 Million


COMMERCIAL INSURED SAVINGS: $195 Million

TOTAL SAVINGS: $316 Million$316 MILLION

GENERIC DRUGS SAVINGS in ALASKA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Arizona $4.5 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN ARIZONA






GENERIC DRUGS SAVINGS in ARIZONA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Arkansas $3.2 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN ARKANSAS


MEDICARE SAVINGS: $1 Billion




GENERIC DRUGS SAVINGS in ARKANSAS


Generic drugs are an essential part of controlling health care spending. Generic drugs saved California $21.5 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN CALIFORNIA

MEDICAID SAVINGS: $2.9 Billion


CASH (non-insured) SAVINGS: $1.3 Billion



GENERIC DRUGS SAVINGS in CALIFORNIA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Colorado $2.9 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN COLORADO






GENERIC DRUGS SAVINGS in COLORADO


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Connecticut $2.9 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN CONNECTICUT






GENERIC DRUGS SAVINGS in CONNECTICUT


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Delaware $716 million in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN DELAWARE






GENERIC DRUGS SAVINGS in DELAWARE


Generic drugs are an essential part of controlling health care spending. Generic drugs saved the District of Columbia $750 million in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN THE DISTRICT OF COLUMBIA






GENERIC DRUGS SAVINGS in DISTRICT OF COLUMBIA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Florida $15 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN FLORIDA





TOTAL SAVINGS: $15 Billion$15 BILLION

GENERIC DRUGS SAVINGS in FLORIDA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Georgia $8.4 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN GEORGIA






GENERIC DRUGS SAVINGS in GEORGIA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Hawaii $824 million in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN HAWAII






GENERIC DRUGS SAVINGS in HAWAII


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Idaho $1.1 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN IDAHO






GENERIC DRUGS SAVINGS in IDAHO


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Illinois $9.8 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN ILLINOIS






GENERIC DRUGS SAVINGS in ILLINOIS


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Indiana $5.6 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN INDIANA




COMMERCIAL INSURED SAVINGS: $3 Billion


GENERIC DRUGS SAVINGS in INDIANA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Iowa $2.9 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN IOWA






GENERIC DRUGS SAVINGS in IOWA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Kansas $2.7 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN KANSAS






GENERIC DRUGS SAVINGS in KANSAS


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Kentucky $5.3 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN KENTUCKY






GENERIC DRUGS SAVINGS in KENTUCKY


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Louisiana $5 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN LOUISIANA






GENERIC DRUGS SAVINGS in LOUISIANA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Maine $1.1 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN MAINE






GENERIC DRUGS SAVINGS in MAINE


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Maryland $4.3 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN MARYLAND






GENERIC DRUGS SAVINGS in MARYLAND


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Massachusetts $6.1 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN MASSACHUSETTS






GENERIC DRUGS SAVINGS in MASSACHUSETTS


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Michigan $8.6 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN MICHIGAN






GENERIC DRUGS SAVINGS in MICHIGAN


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Minnesota $3.9 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN MINNESOTA






GENERIC DRUGS SAVINGS in MINNESOTA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Mississippi $3.2 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN MISSISSIPPI






GENERIC DRUGS SAVINGS in MISSISSIPPI


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Missouri $5.4 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN MISSOURI






GENERIC DRUGS SAVINGS in MISSOURI


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Montana $682 million in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN MONTANA






GENERIC DRUGS SAVINGS in MONTANA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Nebraska $1.7 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN NEBRASKA






GENERIC DRUGS SAVINGS in NEBRASKA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Nevada $1.9 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN NEVADA






GENERIC DRUGS SAVINGS in NEVADA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved New Hampshire $962 million in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN NEW HAMPSHIRE






GENERIC DRUGS SAVINGS in NEW HAMPSHIRE


Generic drugs are an essential part of controlling health care spending. Generic drugs saved New Jersey $6.3 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN NEW JERSEY






GENERIC DRUGS SAVINGS in NEW JERSEY


Generic drugs are an essential part of controlling health care spending. Generic drugs saved New Mexico $1.3 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN NEW MEXICO






GENERIC DRUGS SAVINGS in NEW MEXICO


Generic drugs are an essential part of controlling health care spending. Generic drugs saved New York $20 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN NEW YORK






GENERIC DRUGS SAVINGS in NEW YORK


Generic drugs are an essential part of controlling health care spending. Generic drugs saved North Carolina $8.7 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN NORTH CAROLINA






GENERIC DRUGS SAVINGS in NORTH CAROLINA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved North Dakota $653 million in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN NORTH DAKOTA






GENERIC DRUGS SAVINGS in NORTH DAKOTA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Ohio $10.6 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN OHIO






GENERIC DRUGS SAVINGS in OHIO


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Oklahoma $3.2 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN OKLAHOMA






GENERIC DRUGS SAVINGS in OKLAHOMA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Oregon $2.7 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN OREGON






GENERIC DRUGS SAVINGS in OREGON


GENERIC DRUGS SAVINGS in PENNSYLVANIA

Generic drugs are an essential part of controlling health care spending. Generic drugs saved Pennsylvania $12 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN PENNSYLVANIA







Generic drugs are an essential part of controlling health care spending. Generic drugs saved Rhode Island $1.2 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN RHODE ISLAND






GENERIC DRUGS SAVINGS in RHODE ISLAND


Generic drugs are an essential part of controlling health care spending. Generic drugs saved South Carolina $4.3 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN SOUTH CAROLINA






GENERIC DRUGS SAVINGS in SOUTH CAROLINA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved South Dakota $667 million in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN SOUTH DAKOTA






GENERIC DRUGS SAVINGS in SOUTH DAKOTA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Tennessee $7.1 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN TENNESSEE






GENERIC DRUGS SAVINGS in TENNESSEE


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Texas $18 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN TEXAS






GENERIC DRUGS SAVINGS in TEXAS


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Utah $2 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN UTAH






GENERIC DRUGS SAVINGS in UTAH


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Vermont $443 million in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN VERMONT






GENERIC DRUGS SAVINGS in VERMONT


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Virginia $6.2 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN VIRGINIA






GENERIC DRUGS SAVINGS in VIRGINIA


Generic drugs are an essential part of controlling health care spending. Generic drugs saved Washington $4.4 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN WASHINGTON


MEDICARE SAVINGS: $1 Billion




GENERIC DRUGS SAVINGS in WASHINGTON


Generic drugs are an essential part of controlling health care spending. Generic drugs saved West Virginia $2.4 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN WEST VIRGINIA






GENERIC DRUGS SAVINGS in WEST VIRGINIA


GENERIC DRUGS SAVINGS in WISCONSIN

Generic drugs are an essential part of controlling health care spending. Generic drugs saved Wisconsin $4.4 billion in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN WISCONSIN







Generic drugs are an essential part of controlling health care spending. Generic drugs saved Wyoming $348 million in 2014, according to new data from the 2015 Generic Drug Savings in the U.S. report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).



ONLY

28%DRUG COST

254 BILLION SAVINGS


MEDICAIDSAVINGS

$33.5BILLION

MEDICARESAVINGS

$76.1BILLION




2014 GENERIC DRUG SAVINGS IN WYOMING






GENERIC DRUGS SAVINGS in WYOMING

Legislative News, Studies and Analysis - GENERIC …...cancer ($11.6 billion), anti-bacterials...

Documents

Transcript of Legislative News, Studies and Analysis - GENERIC …...cancer ($11.6 billion), anti-bacterials...